Recent News

• 01.27.2025 - Moleculin Participates in Virtual Investor “What This Means” Segment
• 01.08.2025 - Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026
• 12.11.2024 - Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Recent Filings

• 01.29.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 01.27.2025 - 8-K/A Current report
• 01.27.2025 - EX-99.1 EX-99.1
• 12.09.2024 - EFFECT Notice of Effectiveness
• 12.03.2024 - POS AM Post-Effective amendments for registration statement